Swiss AI in Healthcare: The Aukera Therapeutics Story

A spin-off from the University of Basel has just emerged from stealth, backed by CHF 4.5 million and a biotech heavyweight. This marks a landmark moment for Swiss AI in healthcare.

A New Era in AI-Driven Drug Discovery

Aukera Therapeutics is on a mission to develop novel therapies for diseases linked to the mTOR protein, which is implicated in cancer, neurodegeneration, and rare genetic disorders like Tuberous Sclerosis Complex (TSC).

Founded by Stefan Imseng, the Basel-based company isn't using traditional methods. It has developed a sophisticated, AI-powered drug discovery platform that screened billions of compounds to identify a highly selective inhibitor. This approach promises to create treatments with better efficacy and fewer side effects than existing options.

Backed by Swiss Capital and Industry Leaders

The potential is so significant that it has not only secured CHF 4.5 million in funding from investors including Kickfund and the Zürcher Kantonalbank, but also attracted David Urech, the former CEO of Numab Therapeutics, as both an investor and a board member. Urech stated his decision was driven by the “promise to change the lives of more than one million TSC patients, and the scientific excellence of the Aukera team.”

The Blueprint for Swiss Deep Tech Innovation

This story is more than just another biotech success. It perfectly illustrates the power of the Swiss innovation ecosystem:

World-class academic research from institutions like the University of Basel.
A strong local funding environment.
The ability to attract top-tier industry veterans.

It’s a testament to the credibility and global potential of our homegrown deep tech ventures. The rise of companies like Aukera demonstrates that AI is not just an abstract concept here in Switzerland; it is a fundamental driver of solutions to some of humanity's most complex problems. This model—combining academic excellence with AI-driven R&D and strategic Swiss capital—is becoming a powerful blueprint for success.

From Biotech to Business: AI as a Strategic Driver

The deep application of AI in biotech mirrors what we're seeing across the Swiss SME landscape: intelligent automation is no longer just a tool, but a core strategic driver for solving complex challenges. It's this drive for precision and efficiency that defines our market.